Content
09/06/2024 Palo Alto, CA USA
OrsoBio completed $67 million Series B Round funding. Investors include Woodline Partners (lead), Ascenta Capital (lead), Eli Lilly and Company, Enavate Sciences, Longitude Capital, NuevaBio, Samsara BioCapital.
#Biotech  #Life Science  
About
OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism.
Startup
OrsoBio
https://orsobio.com Claim Profile
Location:
Palo Alto, CA USA
Sector:
Biotech
Life Science
Download StockFan App Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.